# US 2008/0269191 A1 · Compounds for Nonsense Suppression, Use of These Compounds for the Manufacture of a Medicament for Treating Somatic Mutation-Related Diseases

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2008/0269191 A1
- Document ID: US20080269191A1
- Status: Published application
- Kind: A1
- Application number: 11/577,176
- Filed: 2005-10-13
- Published: 2008-10-30
- Earliest claimed: 2004-10-13
- Assignees: PTC Therapeutics, Inc.
- Inventors: Richard Wilde; Ellen Welch; Gary M. Karp
- Web page: https://patentgrep.com/patent/US20080269191A1

## CPC

- C07D 271/06: 1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
- A61P 1/16: for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A61P 3/04: Anorexiants; Antiobesity agents
- A61P 3/06: Antihyperlipidemics
- A61P 3/10: for hyperglycaemia, e.g. antidiabetics
- A61P 5/14: of the thyroid hormones, e.g. T3, T4
- A61P 7/00: Drugs for disorders of the blood or the extracellular fluid
- A61P 7/04: Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
- A61P 9/00: Drugs for disorders of the cardiovascular system
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A61P 11/00: Drugs for disorders of the respiratory system
- A61P 13/12: of the kidneys
- A61P 19/00: Drugs for skeletal disorders
- A61P 19/02: for joint disorders, e.g. arthritis, arthrosis
- A61P 19/08: for bone diseases, e.g. rachitism, Paget's disease
- A61P 21/00: Drugs for disorders of the muscular or neuromuscular system
- A61P 25/00: Drugs for disorders of the nervous system
- A61P 25/16: Anti-Parkinson drugs
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A61P 27/02: Ophthalmic agents
- A61P 29/00: Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P 35/00: Antineoplastic agents
- A61P 35/02: specific for leukemia
- A61P 37/00: Drugs for immunological or allergic disorders
- A61P 37/02: Immunomodulators
- A61P 37/06: Immunosuppressants, e.g. drugs for graft rejection
- A61P 43/00: Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C07D 231/12: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 233/64: with substituted hydrocarbon radicals attached to ring carbon atoms, e.g. histidine
- C07D 249/08: 1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
- C07D 251/24: to three ring carbon atoms
- C07D 261/08: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 263/32: with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D 271/10: 1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
- C07D 271/107: with two aryl or substituted aryl radicals attached in positions 2 and 5
- C07D 277/30: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 285/12: 1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
- C07D 307/68: Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
- C07D 333/24: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 403/04: directly linked by a ring-member-to-ring-member bond
- C07D 405/04: directly linked by a ring-member-to-ring-member bond
- C07D 409/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/04: directly linked by a ring-member-to-ring-member bond
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 413/12: linked by a chain containing hetero atoms as chain links
- C07D 417/04: directly linked by a ring-member-to-ring-member bond
- C07F 9/65306: {containing two nitrogen atoms}
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07F: ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM (metal-containing porphyrins C07D487/22)

## Abstract

The present invention relates to methods, compounds, and compositions for treating or preventing diseases associated with nonsense mutations in an mRNA by administering the compounds or compositions of the present invention. More particularly, the present invention relates to methods, compounds, and compositions for suppressing premature translation termination associated with a nonsense mutation in an mRNA.

## Claims

### Claim 1

A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of a compound of Formula 1:
wherein:
Y and Z are independently selected from N or C;
W is N or CH;
n is 0, 1, 2 or 3;
R1 is hydrogen, a C6 to C8 aryl which is optionally substituted with a carboxy group, or R1 is absent when Z is N;
R2 is hydrogen; a C6 to C8 aryl which is optionally substituted with one, two, or three independently selected Ra groups; a four to seven membered heterocycle which is optionally substituted with one or more independently selected C1-C6 alkyl groups or a three to seven membered heterocycle; or R2 is absent when Y is N;
R is independently selected from a halogen; a carboxy group; a C1-C6 alkyl group optionally substituted with a four to six membered heterocycle, a C6-C8 aryloxy group, or an amino group, wherein the four to six membered heterocycle, C6-C8 aryloxy group, and amino group are optionally substituted with one or two independently selected C1-C6 alkyl or C6-C8 aryl groups which C6-C8 aryl groups are optionally and independently substituted with one or more C1-C6 alkyl groups; a C1-C6 alkoxy; a C6-C8 aryloxy; a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, oxy, C1-C4 alkoxy, or C1-C4 haloalkoxy groups; an amino group optionally substituted with one or two independently selected C6-C8 aryl or C1-C6 alkyl groups, which are optionally substituted with a hydroxy, a C6-C8 aryl, or a nine to ten membered heterocycle having two ring structures; a carbonyl group substituted with a five to six membered heterocycle group; a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups; a nine to ten membered heterocycle having two ring structures; or two R groups, wherein R may also include an oxy group, together with the hetero-bicycle to which they are attached form a twelve to thirteen membered heterocycle having three ring structures;
wherein Ra is a halogen; a C1-C6 alkyl; a C1-C6 alkoxy which is optionally substituted with one or more independently selected halogen groups; a C6-C8 aryl; a four to six-membered heterocycle which is optionally substituted with one or more independently selected oxo groups; a carbonyl which is optionally substituted with a hydroxy or a C1-C6 alkoxy group; a carbamoyl; an amino which is optionally substituted with an independently selected C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted with one or more independently selected halogens or hydroxyl groups; or two Ra groups, wherein Ra may also include an oxy group, together with the C6-C8 aryl group to which they are attached form a nine to ten membered heterocycle having two ring structures, wherein the nine to ten membered heterocycle having two ring structures is optionally substituted with one or more independently selected halogens;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph of said compound of Formula 1.

### Claim 2 (depends on 1)

The method of claim 1, wherein the compound, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate or stereoisomer thereof, is administered as a composition comprising the compound and a pharmaceutically acceptable carrier or diluent.

### Claim 3 (depends on 1)

The method of claim 1, wherein the administration is intravenous.

### Claim 4 (depends on 1)

The method of claim 1, wherein Ra is independently selected from the group consisting of a halogen; a C1 to C6 alkyl; a C6 to C8 aryl group; a carbonyl optionally substituted with a hydroxy group; and a four to six membered heterocycle optionally substituted with one oxo group.

### Claim 5 (depends on 1)

The method of claim 1, wherein Ra is a carbonyl optionally substituted with a hydroxy group.

### Claim 6 (depends on 1)

The method of claim 1, wherein Ra is a four to six membered heterocycle selected from the group consisting of an azetidine group, a pyrrolidine group, a piperidine group, a piperazine group, a morpholine group, a [1,4]-diazepane group, a pyrazole group, an imidazole group, a [1,2,4]-triazole group, a pyridine group, a furan group, and a thiophene group.

### Claim 7 (depends on 1)

The method of claim 1, wherein Ra is a nine to ten membered heterocycle having two ring structures selected from the group consisting of a benzofuran group, a 2,3-dihydro-benzofuran group, a benzo[1,3]dioxole group, a 2,3-dihydro-isoindole group, a 2,3-dihydro-indole group, a 1,2,3,4-tetrahydro-isoquinoline group, and a 1,4-dioxa-8-aza-spiro[4.5]decane group.

### Claim 8 (depends on 1)

The method of claim 1, wherein R2 is selected from the following, wherein the * indicates the bond of attachment:

### Claim 9 (depends on 1)

The method of claim 1, wherein R is selected from the following, wherein the * indicates the bond of attachment:

### Claim 10 (depends on 1)

The method of claim 1, wherein said compound of Formula 1 is a compound of Formula 1-A:

### Claim 11 (depends on 10)

The method of claim 10, wherein n is 1 and R is a carbonyl which is optionally substituted with a hydroxy.

### Claim 12 (depends on 10)

The method of claim 10, wherein n is 1 and the R group is in the 5 or 6 position.

### Claim 13 (depends on 10)

The method of claim 10, wherein R2 is a phenyl group optionally substituted with a carboxy group.

### Claim 14 (depends on 1)

The method of claim 1, wherein said compound of Formula 1 is a compound of Formula 1-B:

### Claim 15 (depends on 14)

The method of claim 14, wherein R1 is a phenyl group optionally substituted with a carbonyl group which is substituted with a hydroxy group.

### Claim 16 (depends on 14)

The method of claim 14, wherein R is a C1-C6 alkyl; a C1-C6 alkoxy; a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, or C1-C4 haloalkoxy groups.

### Claim 17 (depends on 16)

The method of claim 16, wherein the twelve to thirteen membered heterocycle is selected from the following, wherein the * indicates the bond of attachment to R1:

### Claim 18

A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of a compound of Formula 2:
wherein:
Y and Z are independently selected from N or C;
W is N or CH;
n is 0, 1, 2 or 3;
R1 is hydrogen, a C6 to C8 aryl which is optionally substituted with a carboxy group, or R1 is absent when Z is N;
R2 is hydrogen; a C6 to C8 aryl which is optionally substituted with one, two, or three independently selected Ra groups; a four to seven membered heterocycle which is optionally substituted with one or more independently selected C1-C6 alkyl groups or a three to seven membered heterocycle; or R2 is absent when Y is N;
R is independently selected from a halogen; a carboxy group; a C1-C6 alkyl group optionally substituted with a four to six membered heterocycle, a C6-C8 aryloxy group, or an amino group, wherein the four to six membered heterocycle, C6-C8 aryloxy group, and amino group are optionally substituted with one or two independently selected C1-C6 alkyl or C6-C8 aryl groups which C6-C8 aryl groups are optionally and independently substituted with one or more C1-C6 alkyl groups; a C1-C6 alkoxy; a C6-C8 aryloxy; a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, oxy, C1-C4 alkoxy, or C1-C4 haloalkoxy groups; an amino group optionally substituted with one or two independently selected C6-C8 aryl or C1-C6 alkyl groups, which are optionally substituted with a hydroxy, a C6-C8 aryl, or a nine to ten membered heterocycle having two ring structures; a carbonyl group substituted with a five to six membered heterocycle group; a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups; a nine to ten membered heterocycle having two ring structures; or two R groups, wherein R may also include an oxy group, together with the hetero-bicycle to which they are attached form a twelve to thirteen membered heterocycle having three ring structures;
wherein Ra is a hydroxy group; a halogen; a C1-C6 alkyl which is optionally substituted with one or more independently selected halogen or hydroxy groups; a C1-C6 alkoxy which is optionally substituted with one or more independently selected halogen or phenyl groups; a C4-C8 cycloalkyl which is optionally substituted with one or more independently selected C1-C4 alkyl groups; an —Rb group; a —O—Rb group; a four to six-membered heterocycle which is optionally substituted with one or more independently selected C1-C4 alkyl, oxo, or —Rb groups; a nine to ten membered heterocycle having two ring structures; a carbonyl which is optionally substituted with a hydroxy, a C1-C4 alkyl, or a C1-C4 alkoxy group; a carbamoyl which is optionally substituted with one or two independently selected C1-C4 alkyl groups; a nitro group; a cyano group; a thio which is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group; a sulfonyl which is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group; an amino which is optionally substituted with one or two independently selected C1-C6 alkyl, sulfonyl, or carbonyl groups; wherein the C1-C4 alkyl group is optionally substituted with one or more independently selected halogens or hydroxyl groups, wherein the aminosulfonyl group is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group, and wherein the aminocarbonyl group is optionally substituted with a C1-C4 alkyl, a C1-C4 haloalkyl, a benzoxy, or an amino group which is optionally substituted with an —Rb group; or two Ra groups, wherein Ra may also include an oxy group, together with the C6-C8 aryl group to which they are attached form a nine to ten membered heterocycle having two ring structures, wherein the nine to ten membered heterocycle having two ring structures is optionally substituted with one or more independently selected halogens;
wherein —Rb is a C6-C8 aryl which is optionally substituted with one or more groups independently selected from the following: a hydroxy, a halogen, a C1-C4 alkyl group, a C1-C4 haloalkyl group, a C1-C4 alkoxy group, and an amino group which is optionally substituted with one or two independently selected C1-C4 alkyl groups;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph of said compound of Formula 2.

### Claim 19 (depends on 18)

The method of claim 18, wherein the compound, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate or stereoisomer thereof, is administered as a composition comprising the compound and a pharmaceutically acceptable carrier or diluent.

### Claim 20 (depends on 18)

The method of claim 18, wherein the administration is intravenous.

### Claim 21 (depends on 18)

The method of claim 18, wherein Ra is independently selected from the group consisting of a halogen; a C1 to C6 alkyl; a C6 to C8 aryl group; a carbonyl optionally substituted with a hydroxy group; and a four to six membered heterocycle optionally substituted with one oxo group.

### Claim 22 (depends on 18)

The method of claim 18, wherein Ra is a four to six membered heterocycle selected from the group consisting of an azetidine group, a pyrrolidine group, a piperidine group, a piperazine group, a morpholine group, a [1,4]diazepane group, a pyrazole group, an imidazole group, a [1,2,4] triazole group, a pyridine group, a furan group, and a thiophene group.

### Claim 23 (depends on 18)

The method of claim 18, wherein Ra is a nine to ten membered heterocycle having two ring structures selected from a benzofuran group, a 2,3-dihydro-benzofuran group, a benzo[1,3]dioxole group, a 2,3-dihydro-isoindole group, a 2,3-dihydro-indole group, a 1,2,3,4-tetrahydro-isoquinoline group, and a 1,4-dioxa-8-aza-spiro[4.5]decane group.

### Claim 24

A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of a compound of Formula 3:
wherein:
Y and Z are independently selected from N or C;
W is N or CH;
n is 0, 1, 2 or 3;
R1 is absent or a C6 to C8 aryl which is optionally substituted with a carboxy group;
R2 is absent; a C6 to C8 aryl which is optionally substituted with one, two, or three independently selected Ra groups; or a four to seven membered heterocycle which is optionally substituted with one or more C1-C4 alkyl groups, or a four to six membered heterocycle;
R is independently selected from a halogen; a carboxy group; a C1-C6 alkyl group optionally substituted with a C6-C8 aryloxy group, an imidazole group, or an amino group which is optionally substituted with one or two independently selected C1-C6 alkyl or C6-C8 aryl groups; a C1-C6 alkoxy; a C6-C8 aryloxy; a C6-C8 aryl optionally substituted with one or more halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 haloalkoxy groups; an amino group optionally substituted with one or two independently selected C6-C8 aryl or C1-C6 alkyl groups, which are optionally substituted with a hydroxy, a phenyl, or a benzo[1,3]dioxole group; a carbonyl group optionally substituted with a five to six membered heterocycle group; a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups; a nine to ten membered heterocycle having two ring structures; or two R groups together with the hetero-bicycle to which they are attached form a twelve to thirteen membered heterocycle having three ring structures;
wherein Ra is a hydroxy group; a halogen; a C1-C4 alkyl which is optionally substituted with one or more independently selected halogen or hydroxy groups; a C1-C4 alkoxy which is optionally substituted with one or more independently selected halogen or phenyl groups; a C4-C8 cycloalkyl which is optionally substituted with one or more independently selected C1-C4 alkyl groups; an —Rb group; a —O—Rb group; a four to six-membered heterocycle which is optionally substituted with one or more independently selected C1-C4 alkyl, oxo, or —Rb groups; a nine to ten membered heterocycle having two ring structures; a carbonyl which is optionally substituted with a hydroxy, a C1-C4 alkyl, or a C1-C4 alkoxy group; a carbamoyl which is optionally substituted with one or two C1-C4 alkyl groups; a nitro group; a cyano group; a thio which is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group; a sulfonyl which is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group; an amino which is optionally substituted with one or two independently selected C1-C4 alkyl, sulfonyl, or carbonyl groups; wherein the aminosulfonyl group is optionally substituted with a hydroxy, a C1-C4 alkyl, or —Rb group; and wherein the aminocarbonyl group is optionally substituted with a C1-C4 alkyl, a C1-C4 haloalkyl, a benzoxy, or an amino group which is optionally substituted with an —Rb group, or two Ra groups together with the phenyl ring to which they are attached form a benzo[1,3]dioxole optionally substituted with one or more halogens or a 2,3-dihydro-benzofuran group;
wherein —Rb is a C6-C8 aryl which is optionally substituted with one or more of the following: a hydroxy, a halogen, a C1-C4 alkyl group, a C1-C4 haloalkyl group, a C1-C4 alkoxy group, or an amino group which is optionally substituted with one or more C1-C4 alkyl groups;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph of said compound of Formula 3.

### Claim 25 (depends on 24)

The method of claim 24, wherein the compound, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate or stereoisomer thereof, is administered as a composition comprising the compound and a pharmaceutically acceptable carrier or diluent.

### Claim 26 (depends on 1)

The method of claim 1 wherein the administration is intravenous.

### Claim 27

A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of a compound of Formula 4:
wherein:
Y and Z are independently selected from N or C;
W is N or CH;
R1 is hydrogen, a C6 to C8 aryl which is optionally substituted with a carboxy group, or R1 is absent when Z is N;
R2 is hydrogen; a C6 to C8 aryl which is optionally substituted with one, two, or three independently selected Ra groups; a four to seven membered heterocycle which is optionally substituted with one or more independently selected C1-C6 alkyl groups or a three to seven membered heterocycle; or R2 is absent when Y is N;
R3 is hydrogen; a halogen; a carboxy group; or R3, wherein R3 may also include an oxy group, together with R4 and the heterocycle to which they are attached preferably form a twelve to thirteen membered heterocycle with three ring structures;
R4 is hydrogen, a halogen; a carboxy group; a C1-C6 alkyl group; a C1-C6 alkoxy; a C6-C8 aryloxy; a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 haloalkoxy groups; an amino group optionally substituted with one or two independently selected C6-C8 aryl or C1-C6 alkyl groups, which are optionally substituted with a hydroxy, a phenyl, or a benzo[1,3]dioxole group; a carbonyl group substituted with a five to six membered heterocycle group; or a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups; a nine to ten membered heterocycle having two ring structures; or R3 together with R4 and the heterocycle to which they are attached preferably form a twelve to thirteen membered heterocycle with three ring structures;
R5 is independently selected from: hydrogen, a halogen; a carboxy group; a C1-C6 alkyl group optionally substituted with a C6-C8 aryloxy group, an imidazole group, or an amino group which is optionally substituted with one or two independently selected C1-C6 alkyl or C6-C8 aryl groups; a C1-C6 alkoxy; a C6-C8 aryloxy; a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, C1-C4 alkoxy, or C1-C4 haloalkoxy groups; a carbonyl group substituted with a five to six membered heterocycle group; a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups; or a nine to ten membered heterocycle having two ring structures;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph of said compound of Formula 4.

### Claim 28 (depends on 27)

The method of claim 27, wherein R4 is selected from:

### Claim 29 (depends on 27)

The method of claim 27, wherein R5 is selected from the following, wherein the * indicates the bond of attachment:

### Claim 30 (depends on 21, 27)

The method of claim 27, wherein said compound of Formula 4 is a compound of Formula 4-A:
The method of claim 21, wherein R2 is a C6 to C8 aryl, optionally substituted with one, two, or three —Ra groups, wherein Ra is independently selected from: a halogen; a C1 to C6 alkyl; a C1 to C6 haloalkyl; a C1 to C6 alkoxy; a C1 to C6 haloalkoxy; a C6 to C8 aryl group; a carboxy group; a carbamoyl group; an amino group which is optionally substituted with one or two independently selected hydroxy groups, halogens, C1 to C6 alkyls, or C1 to C6 haloalkyls; or a four to six membered heterocycle optionally substituted with an oxo group.

### Claim 31 (depends on 27)

The method of claim 27, wherein said compound of Formula 4 is a compound of Formula 4-B:

### Claim 32 (depends on 27)

The method of claim 27, wherein R1 is a phenyl group optionally substituted with a carboxy group.

### Claim 33

A method of treating or preventing an autoimmune disease, a blood disease, a collagen disease, diabetes, a neurodegenerative disease, a cardiovascular disease, a pulmonary disease, or an inflammatory disease or central nervous system disease comprising administering to a patient in need thereof an effective amount of a compound of Formula 1, 2, 3, or 4, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof.

### Claim 34 (depends on 33)

The method of claim 33, wherein the administration is intravenous.

### Claim 35 (depends on 33)

The method of claim 33, wherein the autoimmune disease is rheumatoid arthritis or graft versus host disease.

### Claim 36 (depends on 33)

The method of claim 33, wherein the inflammatory disease is arthritis.

### Claim 37 (depends on 33)

The method of claim 33, wherein the central nervous system disease is multiple sclerosis, muscular dystrophy, Duchenne muscular dystrophy, Alzheimer's disease, a neurodegenerative disease or Parkinson's disease.

### Claim 38 (depends on 33)

The method of claim 33, wherein the blood disorder is hemophilia, Von Willebrand disease, ataxia-telangiectasia, β-thalassemia or kidney stones.

### Claim 39 (depends on 33)

The method of claim 33, wherein the collagen disease is osteogenesis imperfecta or cirrhosis.

### Claim 40

A method of treating or preventing familial polycythemia, immunodeficiency, kidney disease, muscular dystrophy, heart disease, kidney stones, ataxia-telangiectasia, cystic fibrosis, familial hypercholesterolemia, retinitis pigmentosa, amyloidosis, hemophilia, Alzheimer's disease, Tay Sachs disease, Niemann Pick disease, Parkinson's disease, atherosclerosis, giantism, dwarfism, hyperthyroidism, aging, obesity, Duchenne muscular dystrophy, epidermolysis bullosa or Marfan syndrome comprising administering to a patient in need thereof an effective amount of a compound of Formula 1, 2, 3, or 4, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof.

### Claim 41 (depends on 40)

The method of claim 40, wherein the administration is intravenous.

### Claim 42

A method of treating or preventing cancer in a human comprising administering to a human in need thereof an effective amount of a compound of Formula 1, 2, 3, or 4, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof.

### Claim 43 (depends on 42)

The method of claim 42, wherein the administration is intravenous.

### Claim 44 (depends on 42)

The method of claim 42, wherein the cancer is of the head and neck, eye, skin, mouth, throat, esophagus, chest, bone, blood, lung, colon, sigmoid, rectum, stomach, prostate, breast, ovaries, kidney, liver, pancreas, brain, intestine, heart or adrenals.

### Claim 45 (depends on 42)

The method of claim 42, wherein the compound, or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof, comprises a pharmaceutically acceptable carrier or diluent.

### Claim 46 (depends on 42)

The method of claim 42, wherein the cancer is a solid tumor.

### Claim 47 (depends on 42)

The method of claim 42, wherein the cancer is sarcoma, carcinoma, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, Kaposi's sarcoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma, retinoblastoma, a blood-born tumor or multiple myeloma.

### Claim 48 (depends on 42)

The method of claim 42, wherein the cancer is acute lymphoblastic leukemia, acute lymphoblastic B-cell leukemia, acute lymphoblastic T-cell leukemia, acute myeloblastic leukemia, acute promyelocytic leukemia, acute monoblastic leukemia, acute erythroleukemic leukemia, acute megakaryoblastic leukemia, acute myelomonocytic leukemia, acute nonlymphocyctic leukemia, acute undifferentiated leukemia, chronic myelocytic leukemia, chronic lymphocytic leukemia, hairy cell leukemia, or multiple myeloma.

### Claim 49

A method of treating or preventing a disease associated with a mutation of the p53 gene comprising administering to a patient in need thereof an effective amount of a compound of Formula 1, 2, 3, or 4 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof.

### Claim 50 (depends on 49)

The method of claim 49, wherein the administration is intravenous.

### Claim 51 (depends on 49)

The method of claim 49, wherein the disease is sarcoma, carcinomas, fibrosarcoma, myxosarcoma, liposarcoma, chondrosarcoma, osteogenic sarcoma, chordoma, angiosarcoma, endotheliosarcoma, lymphangiosarcoma, lymphangioendotheliosarcoma, synovioma, mesothelioma, Ewing's tumor, leiomyosarcoma, rhabdomyosarcoma, colon carcinoma, pancreatic cancer, breast cancer, ovarian cancer, prostate cancer, squamous cell carcinoma, basal cell carcinoma, adenocarcinoma, sweat gland carcinoma, sebaceous gland carcinoma, papillary carcinoma, papillary adenocarcinomas, cystadenocarcinoma, medullary carcinoma, bronchogenic carcinoma, renal cell carcinoma, hepatoma, bile duct carcinoma, choriocarcinoma, seminoma, embryonal carcinoma, Wilms' tumor, cervical cancer, testicular tumor, lung carcinoma, small cell lung carcinoma, bladder carcinoma, epithelial carcinoma, glioma, astrocytoma, medulloblastoma, craniopharyngioma, ependymoma, Kaposi's sarcoma, pinealoma, hemangioblastoma, acoustic neuroma, oligodendroglioma, menangioma, melanoma, neuroblastoma or retinoblastoma.

### Claim 52

A method of inhibiting the growth of a cancer cell comprising contacting the cancer cell with an effective amount of a compound of Formula 1, 2, 3, or 4 or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph thereof.

### Claim 53

A method for selectively producing a protein in a mammal comprising transcribing a gene containing a nonsense mutation in the mammal; and providing an effective amount of a compound of the present invention to said mammal, wherein said protein is produced by said mammal.

### Claim 54

A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of one or more compounds from Compounds 1 through 142.

### Claim 55

A method of treating or preventing a disease resulting from a somatic mutation comprising administering to a patient in need thereof an effective amount of one or more compounds from Compounds 19, 20, 42, 49, 53, 56, 58, 59, 85, 91, 94, 96, 100, 101, and 102.

### Claim 56

A compound of Formula 1
wherein:
Y and Z are independently selected from N or C;
W is N or CH;
n is 0, 1, 2 or 3;
R1 is hydrogen, a C6 to C8 aryl which is optionally substituted with a carboxy group, or R1 is absent when Z is N;
R2 is hydrogen; a C6 to C8 aryl which is optionally substituted with one, two, or three independently selected Ra groups; a four to seven membered heterocycle which is optionally substituted with one or more independently selected C1-C6 alkyl groups or a three to seven membered heterocycle; or R2 is absent when Y is N;
R is independently selected from a halogen; a carboxy group; a C1-C6 alkyl group optionally substituted with a four to seven membered heterocycle, a C6-C8 aryloxy group, or an amino group, wherein the four to seven membered heterocycle, C6-C8 aryloxy group, and amino group are optionally substituted with one or two independently selected C1-C6 alkyl or C6-C8 aryl groups which C6-C8 aryl groups are optionally and independently substituted with one or more C1-C6 alkyl groups; a C1-C6 alkoxy; a C6-C8 aryloxy; a C6-C8 aryl optionally substituted with one or more independently selected halogen, C1-C4 alkyl, C1-C4 haloalkyl, oxy, C1-C4 alkoxy, or C1-C4 haloalkoxy groups; an amino group optionally substituted with one or two independently selected C6-C8 aryl or C1-C6 alkyl groups, which are optionally substituted with a hydroxy, a C6-C8 aryl, or a nine to ten membered heterocycle having two ring structures; a carbonyl group optionally substituted with a five to six membered heterocycle group; a four to seven membered heterocycle group optionally substituted with one more C1-C4 alkyl or oxo groups; a nine to ten membered heterocycle having two ring structures; or two R groups, wherein R may also include an oxy group, together with the hetero-bicycle to which they are attached form a twelve to thirteen membered heterocycle having three ring structures;
wherein Ra is a halogen; a C1-C6 alkyl; a C1-C6 alkoxy which is optionally substituted with one or more independently selected halogen groups; a C6-C8 aryl; a four to seven membered heterocycle which is optionally substituted with one or more independently selected oxo groups; a carbonyl which is substituted with a hydroxy or a C1-C6 alkoxy group; a carbamoyl; an amino which is optionally substituted with an independently selected C1-C6 alkyl group, wherein the C1-C6 alkyl group is optionally substituted with one or more independently selected halogens or hydroxyl groups; or two Ra groups, wherein Ra may also include an oxy group, together with the C6-C8 aryl group to which they are attached form a nine to ten membered heterocycle having two ring structures, wherein the nine to ten membered heterocycle having two ring structures is optionally substituted with one or more independently selected halogens;
or a pharmaceutically acceptable salt, hydrate, solvate, clathrate, racemate, stereoisomer, or polymorph of said compound of Formula 1.

### Claim 57 (depends on 56)

The compound of claim 56, wherein the compound is selected from Compounds 1-142.

### Claim 58 (depends on 56)

The compound of claim 56, wherein the compound is selected from Compounds 19, 20, 42, 49, 53, 56, 58, 59, 85, 91, 94, 96, 100, 101, and 102.

### Claim 59

A compound having the formula (Compound NO: 1):
